Global state: clinically significant response in global state ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · patients with schizophrenia
1 finding from 1 review
Mental state: average score for negative symptoms ‐ by short term Manchester Scale, negative subset endpoint. Scale from: 0 to 20. · patients with schizophrenia
1 finding from 1 review
Mental state: average score for depressive and anxious symptoms ‐ by medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: average score ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety assessments ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in global state: mean CGI score (high = poor) Short term (8 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · people with treatment‐resistant schizophrenia
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Weight gain · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG showed no clear difference in global state: No clinically important response ‐ short term compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia
It is very uncertain whether SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG changes specific adverse effects: 1a. CNS ‐ short term ‐ movement disorder ‐… compared with ANY ANTIPSYCHOTIC DRUG (very low certainty).
1 finding from 1 review
Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review
Specific adverse effects: 4. Gastrointestinal system ‐ short term ‐ salavation ‐ too much · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 4. Gastrointestinal system ‐ short term ‐… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower mental state: 1a. General ‐ No clinical important improvement ‐ BPRS… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review
Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS) · patients with schizophrenia
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG showed no clear difference in mental state: 2a. Negative symptoms ‐ No clinical important… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
1 finding from 1 review